SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
Open Access
- 20 January 2021
- Vol. 70 (4), 635-640
- https://doi.org/10.1136/gutjnl-2020-324000
Abstract
The COVID-19 pandemic has claimed the lives of nearly 2 million people worldwide.1 Following rapid sequencing of SARS-CoV-2, pharmaceutical companies and academic institutions rapidly generated vaccine candidates on the back of a variety of both established and novel vaccine platforms.2–4 Vaccines accelerated at unprecedented pace to phase 3 development, and in December 2020, two mRNA vaccines and one inactivated vaccine were authorised for use in a number of countries. Additional vaccine platforms and candidates are in late stages of phase 3 testing.5 Prioritisation of vaccine access is generally determined by regional health authorities on the basis of risk of SARS-CoV-2 exposure and risk of developing complications from COVID-19 in order to equitably protect and promote global public well-being.6–8Keywords
This publication has 38 references indexed in Scilit:
- Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab TherapyInflammatory Bowel Diseases, 2016
- Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case–Control and Cohort StudiesClinical Gastroenterology and Hepatology, 2015
- The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2015
- Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial resultsGut, 2014
- Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infectionNature Biotechnology, 2012
- Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*Inflammatory Bowel Diseases, 2012
- Immunogenicity and safety of influenza vaccination in children with inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic reviewVaccine, 2011
- H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyGut, 2011
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010